Department of Surgery, National University of Singapore, Singapore 119228, Singapore.
School of Applied Sciences, Temasek Polytechnic, Singapore 529757, Singapore.
World J Gastroenterol. 2021 Aug 14;27(30):5019-5036. doi: 10.3748/wjg.v27.i30.5019.
The gut microbiome is a complex microbial community, recognized for its potential role in physiology, health, and disease. The available evidence supports the role of gut dysbiosis in pancreatic disorders, including acute pancreatitis (AP). In AP, the presence of gut barrier damage resulting in increased mucosal permeability may lead to translocation of intestinal bacteria, necrosis of pancreatic and peripancreatic tissue, and infection, often accompanied by multiple organ dysfunction syndrome. Preserving gut microbial homeostasis may reduce the systemic effects of AP. A growing body of evidence suggests the possible involvement of the gut microbiome in various pancreatic diseases, including AP. This review discusses the possible role of the gut microbiome in AP. It highlights AP treatment and supplementation with prebiotics, synbiotics, and probiotics to maintain gastrointestinal microbial balance and effectively reduce hospitalization, morbidity and mortality in an early phase. It also addresses novel therapeutic areas in the gut microbiome, personalized treatment, and provides a roadmap of human microbial contributions to AP that have potential clinical benefit.
肠道微生物群是一个复杂的微生物群落,其在生理学、健康和疾病方面的潜在作用已得到认可。现有证据支持肠道微生态失调在胰腺疾病中的作用,包括急性胰腺炎(AP)。在 AP 中,肠道屏障损伤导致黏膜通透性增加,可能导致肠道细菌易位、胰腺和胰周组织坏死以及感染,常伴有多器官功能障碍综合征。维持肠道微生物群的平衡可能会减轻 AP 的全身影响。越来越多的证据表明,肠道微生物群可能参与了各种胰腺疾病,包括 AP。这篇综述讨论了肠道微生物群在 AP 中的可能作用。它强调了 AP 治疗和补充益生元、合生元和益生菌以维持胃肠道微生物平衡,并在早期有效降低住院率、发病率和死亡率的作用。它还探讨了肠道微生物群的新治疗领域、个性化治疗,并提供了人类微生物对 AP 潜在临床益处的贡献路线图。